Lineage Cell Therapeutics Provides End of Year Shareholder Letter
The Pharma Data
DECEMBER 27, 2020
NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. CARLSBAD, Calif.–( –( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.
Let's personalize your content